PubMed Health⌕ Search

Biomedical subjects

O Vanderbeke

Publications and source records attributed to O Vanderbeke.

12 recordsLinked to original sources
PubMed1981

[Clinical results with the antimycotic agent ciclopiroxolamine (author's transl)].

After a brief account of the laboratory and animal studies of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt (ciclopiroxolamine, Cic, Hoe 296, Batrafen) and an outline of previous clinical trials, the results of a double-blind trial with Cic cream and clotrimazole cream are reported, together with those of a large-scale trial of Cic cream in consulting practice. Used for the treatment of skin disorders diagnosed as mycoses, the effectiveness rate of Cic cream ranged from 79 to 98%, depending on the criterion used for assessment. The double-blind trial did not reveal any significant differences between its effect and that of clotrimazole cream. The incidence of side-effects can be regarded as minimal.

Antifungal Agents↗
PubMed1979

Single and divided doses of penbutolol.

Penbutolol, a nonselective beta-adrenoreceptor antagonist, induced reduction of exercise-induced heartbeats for at least 24 hr after a single 40-mg oral dose, and was equipotent with respect to a 2 X 20-mg regimen over the same period. Ingestion for 7 days did not influence the pharmacodynamics or pharmacokinetics of penbutolol, and there was no cumulation of drug in serum. A relationship was found between the logarithms of measurable serum concentrations of penbutolol and the percentage reduction of total heartbeats. Absorption of oral penbutolol appeared to be reduced when administered in the evening. Since beta-adrenoceptor activity was relatively unchanged between 13 and 24 hr after a single 40-mg dose of penbutolol, there is a possibility that an active metabolite or metabolites may contribute to prolonged duration of action.

Adult↗
PubMed1979

Pharmacokinetics of single and multiple doses of clobazam in humans.

1. The pharmacokinetics of clobazam and its biotransformation product N-desmethylclobazam were investigated after single and multiple doses in normal subjects. 2. The relevant physicochemical properties of clobazam were measured and are presented. Different assay methods (radiochemical, fluorimetric and gas chromatographic) were applied and the results correlated. 3. After single doses the pharmacokinetic profile of clobazam includes time to peak levels 1--4 h after dosing, peak levels increasing linearly with the logarithm of dose, and terminal half-lives of about 18 hours. At least 87% of an oral dose is absorbed, as indicated by urinary recovery of labelled material. 4. In multiple-dose studies unchanged clobazam levelled off at minimum steady-state concentrations within one week of dosing. During 28 d of medication N-desmethylclobazam accumulated to near steady-state levels about eight times higher than those of the unchanged compound. 5. No pharmacokinetic interactions were discovered between clobazam and the antidepressant nomifensine.

Anti-Anxiety Agents↗
PubMed1978

Plasma cortisol levels in normal volunteers receiving either betamethasone valerate or desoximetasone by topical application.

Desoximetasone (Topisolon; Hoechst), a new topical steroid, and betamethasone 17-valerate were compared with respect to their effects on hypothalamic-pituitary-adrenal function as evidenced by plasma cortisol concentrations. Three grams of each test preparation were applied daily for 21 days to intact skin of the ventral aspects of alternate forearms of 15 normal volunteers. Five received betamethasone 17-valerate 0.1%, 5 desoximetasone 0.05%, and 5 desoximetasone 0.25%. Plasma cortisol levels were determined before and after the initial applications on days 1, 3, 10, 17, 22, 24 and 28. These values were compared with the mean control values by analysis of covariance. There was no significant difference in plasma cortisol levels. The value of performing similar studies on larger skin areas and with larger doses is discussed.

Administration, Topical↗
PubMed1978

Dose-response study with a new LH-RH analogue, D-Ser (TBU)6 LH-RH 1-9 (EA)10 during the follicular phase of the menstrual cycle.

D-Ser (TBU)6 LH-RH 1-9 (EA)10 (HOE 766) a highly active LH-RH analogue, was studied with regard to its effects on the release of follicle stimulating hormone (FSH), luteinizing hormone (LH) and oestradiol-17beta (Oe2) during the follicular phase of the menstrual cycle. Forty-two regularly menstruating women were allowed to five different treatment groups with different doses (1.25 microgram; 2.5 microgram; 5.0 microgram; 10.0 microgram; 20.0 microgram) of HOE 766 given as intravenous bolus injections and the plasma concentrations of FSH, LH and Oe2 were measured up to 24 h after injection using specific radioimmunoassays. In the majority of cases, peak values of both FSH and LH occurred 4 h after injection being significantly different from pre-injection levels (P less than 0.02 in the 1.25 microgram treatment group, P less than 0.005 for the other treatment groups). Statistical analysis of maximum values as well as the absolute and relative increase in the different treatment groups revealed a dose-dependent effect of HOE 766. Maximum values of Oe2 occurred 8 h after injection and were found to be significantly different from pre-injection levels (P less than 0.005). However, no dose dependent effect was observed. It was concluded that HOE 766 is a potent and long-acting stimulator of FSH, LH and OE2 release in women. The effect of HOE 766 is dose dependent for FSH and LH but not for Oe2.

Adult↗
PubMed1975

Method of collecting urine and comparative investigation of quantities excreted by cats and dogs after administration of furosemide.

A method is described for precise investigation of diuresis and saluresis in cats, using trained animals in a special diuresis apparatus. Furosemide given intramuscularly (IM) to cats at the dose level of 10 mg/kg produced slight untoward reactions of short duration. Therefore, this dose lies at the upper limit of tolerance. Saluretic and diuretic effect of 5 different doses of furosemide was investigated in 4 cats and 20 dogs. A dose-dependent increase in diuresis was achieved in cats given doses of furosemide ranging from 1.25 to 10 mg/kg. In the dog, the range of effectiveness was broader. In both species, there was a parallel increase in the excretion of sodium and chloride ions. The excretion of potassium ions in the cat remained unaffected, whereas in the dog, there was a dose-dependent increase in potassium ion excretion, which became especially distinct when large doses were given. A direct comparison of total saluretic and diuretic values in the dog and cat after IM administration of furosemide was not possible, since the calculated straight lines had different slopes, and their points of intersection lay outside the scope of this study. A difference can be assumed to exist between dog and cat in the mode of action of diuresis and saluresis after administration of furosemide.

Animals↗